NICE says Vosevi OK for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has today issued a technology appraisal guidance (TAG) for Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg, SOF/VEL/VOX), recommending use of the drug on the National Health Service.
The drug combination is a 12-week treatment regimen for patients with any genotype of chronic hepatitis C virus (HCV) infection, without cirrhosis or with compensated cirrhosis, who have previously failed therapy with a direct-acting antiviral (DAA) - containing regimen. It was approved by the regulatory agencies in the USA and Europe in July last year.
Vosevi is US biotech major Gilead Sciences’ (Nasdaq: GILD) fourth sofosbuvir-based treatment to be recommended for the treatment of chronic HCV infection, and complements the existing portfolio in demonstrating high cure rates across a range of DAA experienced and naïve patients, the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze